Cardiol Therapeutics Inc Class A
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.8786
- Today's High:
- $0.9281
- Open Price:
- $0.9253
- 52W Low:
- $0.45
- 52W High:
- $1.7
- Prev. Close:
- $0.935
- Volume:
- 190112
Company Statistics
- Market Cap.:
- $43.67 million
- Book Value:
- 0.711
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $78760
- Profit Margin:
- 0%
- Return on Assets TTM:
- -37.22%
- Return on Equity TTM:
- -50.65%
Company Profile
Cardiol Therapeutics Inc Class A had its IPO on 2019-01-15 under the ticker symbol CRDL.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Cardiol Therapeutics Inc Class A has a staff strength of 0 employees.
Stock update
Shares of Cardiol Therapeutics Inc Class A opened at $0.93 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.88 - $0.93, and closed at $0.92.
This is a -2.01% slip from the previous day's closing price.
A total volume of 190,112 shares were traded at the close of the day’s session.
In the last one week, shares of Cardiol Therapeutics Inc Class A have slipped by -8.38%.
Cardiol Therapeutics Inc Class A's Key Ratios
Cardiol Therapeutics Inc Class A has a market cap of $43.67 million, indicating a price to book ratio of 1.0556 and a price to sales ratio of 1069.351.
In the last 12-months Cardiol Therapeutics Inc Class A’s revenue was $0 with a gross profit of $78760 and an EBITDA of $-39159128. The EBITDA ratio measures Cardiol Therapeutics Inc Class A's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cardiol Therapeutics Inc Class A’s operating margin was 0% while its return on assets stood at -37.22% with a return of equity of -50.65%.
In Q1, Cardiol Therapeutics Inc Class A’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cardiol Therapeutics Inc Class A’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cardiol Therapeutics Inc Class A’s profitability.
Cardiol Therapeutics Inc Class A stock is trading at a EV to sales ratio of 178.8107 and a EV to EBITDA ratio of 0.0181. Its price to sales ratio in the trailing 12-months stood at 1069.351.
Cardiol Therapeutics Inc Class A stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $52.69 million
- Total Liabilities
- $7.12 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $44138
- Dividend Payout Ratio
- 0%
Cardiol Therapeutics Inc Class A ended 2024 with $52.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $52.69 million while shareholder equity stood at $45.56 million.
Cardiol Therapeutics Inc Class A ended 2024 with $0 in deferred long-term liabilities, $7.12 million in other current liabilities, in common stock, $-121537846.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.47 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Cardiol Therapeutics Inc Class A’s total current assets stands at $52.11 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $197826.00 compared to accounts payable of $0 and inventory worth $0.
In 2024, Cardiol Therapeutics Inc Class A's operating cash flow was $0 while its capital expenditure stood at $44138.
Comparatively, Cardiol Therapeutics Inc Class A paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.92
- 52-Week High
- $1.7
- 52-Week Low
- $0.45
- Analyst Target Price
- $4.48
Cardiol Therapeutics Inc Class A stock is currently trading at $0.92 per share. It touched a 52-week high of $1.7 and a 52-week low of $1.7. Analysts tracking the stock have a 12-month average target price of $4.48.
Its 50-day moving average was $0.96 and 200-day moving average was $0.7 The short ratio stood at 1.41 indicating a short percent outstanding of 0%.
Around 442.4% of the company’s stock are held by insiders while 1399.2% are held by institutions.
Frequently Asked Questions About Cardiol Therapeutics Inc Class A
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.